Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Investment Manager

Bellevue Asset Management AG

BB Biotech’s Investment Manager is Bellevue Asset Management AG. Bellevue Asset Management AG is subject to supervision by the Swiss Financial Market Supervisory Authority (FINMA) and it has been issued a license as an authorized manager of collective investment schemes. Bellevue Asset Management AG is wholly owned by Bellevue Group AG, an independent Swiss financial boutique listed on the SIX Swiss Exchange. Bellevue Asset Management provides administrative services in connection with the investment activities and organizational operations of BB Biotech AG. This basically comprises the following services:

  • Portfolio Management
  • Investor Relations
  • Marketing & Communications
  • Finance
  • Administration

Investment Management Team

Bellevue Asset Management AG has a team of proven biotech specialists with a successful track record who manage the investments in the biotech sector's most attractive players. The team's academic expertise and extensive experience, its long history of collaboration and interest in all fields of medicine as well as in biochemistry and business fundamentals ensure an inspiring and constructive interdisciplinary dialog within the team and with the Board of Directors as well as with external experts such as physicians and analysts.

  • head BB Biotech & executive board member Bellevue asset management

    head BB Biotech & executive board member Bellevue asset management

    Dr. Christian Koch

    Dr. Christian Koch joined Bellevue Asset Management in 2014. From 2013-2014 he was a sell-side Pharma & Biotech equity analyst at Bank am Bellevue in Küsnacht and from 2010-2013 a Research Associate at the Institute of Pharmaceutical Sciences at ETH Zurich. He holds a PhD in Computer-Assisted Drug Design from ETH Zurich and studied Bioinformatics from Goethe University Frankfurt.

  • Deputy Head & investment analyst

    Deputy Head & investment analyst

    Dr. Maurizio Bernasconi

    Dr. Maurizio Bernasconi joined Bellevue Asset Management in 2017. Prior he was a sell-side equity analyst in the Pharma & Biotech department of Bank am Bellevue. Maurizio Bernasconi has a master's degree in chemistry at Swiss Federal Institute of Technology (ETH), Zurich, a PhD in organic chemistry at the University of Basel and an MBA in International Healthcare Management from the Frankfurt School of Finance.

  • Head US Research & Investment Analyst

    Head US Research & Investment Analyst

    Dr. Kyle Rasbach 

    Dr. Kyle Rasbach joined Bellevue Research Inc / New York in September 2025. Previously, he held senior positions at Eventide Asset Management, Pappas Capital, Lexeo Therapeutics, Zentalis Pharmaceuticals, and T. Rowe Price. He earned a PhD and PharmD in Pharmacology and Pharmacy from the Medical University of South Carolina and an MBA from The Citadel. 

  • Investment Analyst

    Investment Analyst

    Dr. Jordan Baumhardt

    Dr. Jordan Baumhardt joined Bellevue Research Inc / New York in October 2025 as Investment Analyst. Prior to joining Bellevue, he held roles at Lexeo Therapeutics, Zentalis Pharmaceuticals, Eventide Asset Management, and LifeSci Capital. He holds a PhD in Pharmacology and Molecular Biophysics from the University of Texas Southwestern Medical Center and a BSc in Biochemistry and Molecular Biology from Illinois State University.

  • investment analyst

    investment analyst

    Dr. Anna Guinot Aguado

    Dr. Anna Guinot Aguado joined Bellevue Asset Management in 2024. She previously worked at Nextech Invest, a European Biotech VC focused on oncology, where she gained investment experience in both private and public markets. Before her time at Nextech, Anna completed a PostDoc at the University Children's Hospital Zurich (Kispi) in the Oncology division and at the institute of physiology at the University of Zurich. She holds a PhD in Stem Cell & Cancer Biology from the University of Cambridge, after studying Biochemistry in Valencia and Molecular & Cell Biology in Paris.

  • AI & data scientist

    AI & data scientist

    Dr. Can Buldun-Gora

    Dr. Can Buldun-Gora joined Bellevue Asset Management in 2022. From 2018 to 2022 he was a Computational Scientist at Roche Pharma Research & Early Development, focusing on data science and software solutions for next-generation antibody engineering. Can Buldun-Gora holds a PhD in Biochemistry from the University of Oxford and a BSc in Biochemistry & Cell Biology from Jacobs University Bremen.

  • AI & data scientist

    AI & data scientist

    Dr. Olivia Woolley 

    Dr. Olivia Woolley joined Bellevue Asset Management in 2022. She is a member of the investment management team of BB Biotech. Previously she was associate director data science at Novartis, working in Technical Research and Development. Before entering industry she was a postdoctoral researcher at the Swiss Federal Institute of Technology (ETH), Zurich, in the area of digital epidemiology and complex networks. Olivia holds a PhD and MSc in Applied Mathematics from Northwestern University and a BSc in Mathematical and Computational Science from Stanford University.

  • AI & data scientist

    AI & data scientist

    Dr. Samuel Croset

    Dr. Samuel Croset joined Bellevue Asset Management in 2020. He previously worked for Roivant Sciences from 2018-2020 as data scientist supporting investment decisions in drug projects as well as leading a team focused on the analysis of real-world data. Prior to that, he started his professional career at Roche as data scientist in the research department (2014-2018). Samuel holds a Ph.D. in Bioinformatics from the University of Cambridge, a MS in Bioinformatics and a MS in Biochemistry from the University of Geneva.